11.7
CiteScore
7.9
Impact Factor
Turn off MathJax
Article Contents

Activating death receptor 5 exposes a cancer cell vulnerability to natural killer and T cell attack

doi: 10.1016/j.jgg.2026.10.015
Funds:

2024A04J6484 from the Guangdong Basic and Applied Basic Research Foundation (L.W.)

Screeninc infrastructure KWF 12539-Beijersbergen (R.B.) K.K.D. was supported by a ZonMW Veni fellowship (09150162210100) and a KWF Young Investigator Grant (2025-EXPL/16959). R.X. is also supported by National Natural Science Foundation of China (82322047 and 82173035), the National Key Research and Development Project of China (2022YFC3400902), the Beijing Municipal Natural Science Foundation (Z240016), the Beijing Nova Program (20230434854 and 20250484986), and Clinical Medicine Plus X Young Scholars Project of Peking University (PKU2024LCXQ002 and PKU2025PKULCXQ038). Research at the Netherlands Cancer Institute is supported by institutional grants of the Dutch Cancer Society and of the Dutch Ministry of Health, Welfare and Sport.

This work was supported by the 2024ZD0525000 from the National Health Commission of the PRC-Noncommunicable Chronic Diseases-National Science and Technology Major Project (L.W. and R.X.)

YTP-SYSUCC-0055 from the Young Talents Program of Sun Yat-sen University Cancer Center (to L.W.). R.B. was supported by the European Research Council (ERC-787925), 19-051-ASP from the Mark Foundation (R.B.), ASP-II grant-Bernards 2023 (R.B.), KWF-12539 from the Dutch Cancer Society (R.B.), LSH-TKI-LSHM20083 from Health Holland (R.B.)

2023ZT10Y094 from Guangdong Pearl River Talent Program-innovation and entrepreneurship team

2024YFA0918400 from the National Key Research and Development Program of China (L.W.)

82521103, W2432050, W2421020, and 82372695 from the National Natural Science Foundation of China (L.W.)

  • Received Date: 2026-09-07
  • Accepted Date: 2026-10-29
  • Rev Recd Date: 2026-10-24
  • Available Online: 2026-11-04
  • Immunotherapy has revolutionized cancer care, yet resistance frequently undermines its efficacy. Although tumor-intrinsic resistance pathways have been mapped, how immune pressure regulates death-receptor vulnerability and anti-apoptotic buffering remains less defined. Using genome-wide CRISPR-Cas9 screening in cancer cells co-cultured with natural killer (NK) cells, we identify CFLAR, encoding cFLIP, as a dominant suppressor of death-receptor signaling that impairs NK- and T-cell cytotoxicity. CFLAR depletion sensitizes cancer cells to NK- and T-cell attack in vitro and in vivo. Single-cell and spatial transcriptomic analyses link high CFLAR expression to reduced lymphocyte infiltration and poorer responses to immune checkpoint blockade. Mechanistically, immune effector cell-induced inflammation increases CFLAR and death receptor 5 (DR5) expression in association with p38–MAPK signaling, balancing survival and death under immune pressure. The DR5 agonist conatumumab enhances lymphocyte-mediated killing and improves responses to cellular therapies, checkpoint blockade, and chemo-immunotherapy. Combining DR5 agonism with NKG2A blockade co-activates NK- and T-cell responses and overcomes anti-PD-1 resistance in MHC-I-deficient tumors. These findings identify the DR5–cFLIP axis as an immune-pressure-associated, pharmacologically targetable vulnerability and support rational combinations of DR5 agonists with multiple immunotherapies for refractory cancers.
  • loading
  • Alim, L.F., Keane, C., Souza-Fonseca-Guimaraes, F., 2024. Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Curr. Opin. Immunol. 86, 102409.
    Andre, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Blery, M., Bonnafous, C., Gauthier, L., Morel, A., et al., 2018. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731-1743.
    Anfossi, N., Andre, P., Guia, S., Falk, C.S., Roetynck, S., Stewart, C.A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al., 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331-342.
    Beck, J.D., Diken, M., Suchan, M., Streuber, M., Diken, E., Kolb, L., Allnoch, L., Vascotto, F., Peters, D., Beissert, T., et al., 2024. Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell 42, 1467-1470.
    Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., et al., 2015. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med 373, 1627-1639.
    Burtness, B., Harrington, K.J., Greil, R., Soulieres, D., Tahara, M., de Castro, G., Jr., Psyrri, A., Baste, N., Neupane, P., Bratland, A., et al., 2019. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915-1928.
    Caronni, N., La Terza, F., Vittoria, F.M., Barbiera, G., Mezzanzanica, L., Cuzzola, V., Barresi, S., Pellegatta, M., Canevazzi, P., Dunsmore, G., et al., 2023. IL-1beta(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415-422.
    Casagrande Raffi, G., Chen, J., Feng, X., Chen, Z., Lieftink, C., Deng, S., Mo, J., Zeng, C., Steur, M., Wang, J., et al., 2024. An antibiotic that mediates immune destruction of senescent cancer cells. Proc. Natl. Acad. Sci. U. S. A. 121, e2417724121.
    Casagrande Raffi, G., Kuiken, H.J., Lieftink, C., Bernards, R., Beijersbergen, R.L., Wang, L., 2025. Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states. Nat. Protoc. 21, 1896-1926.
    Cha, J.H., Chan, L.C., Li, C.W., Hsu, J.L., Hung, M.C., 2019. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell. 76, 359-370.
    Chalabi, M., Fanchi, L.F., Dijkstra, K.K., Van den Berg, J.G., Aalbers, A.G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G.L., Snaebjornsson, P., et al., 2020. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566-576.
    Chen, H.A., Ho, Y.J., Mezzadra, R., Adrover, J.M., Smolkin, R., Zhu, C., Woess, K., Bernstein, N., Schmitt, G., Fong, L., et al., 2023. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 13, 432-453.
    Chen, J.J., Chou, C.W., Chang, Y.F., Chen, C.C., 2008. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J. Immunol. 180, 8030-8039.
    Chen, K., Wang, Q., Liu, X., Tian, X., Dong, A., Yang, Y., 2023. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. J. Transl. Med. 21, 210.
    Chen, Y., Wang, D., Li, Y., Qi, L., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al., 2024. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42, 1268-1285.
    Chen, Z., Zhang, G., Ren, X., Yao, Z., Zhou, Q., Ren, X., Chen, S., Xu, L., Sun, K., Zeng, Q., et al., 2023. Cross-talk between myeloid and b cells shapes the distinct microenvironments of primary and secondary liver cancer. Cancer Res. 83, 3544-3561.
    Davidovich, P., Higgins, C.A., Najda, Z., Longley, D.B., Martin, S.J., 2023. cFLIP(L) acts as a suppressor of TRAIL- and Fas-initiated inflammation by inhibiting assembly of caspase-8/FADD/RIPK1 NF-kappaB-activating complexes. Cell. Rep. 42, 113476.
    de Miguel, D., Ramirez-Labrada, A., Uranga, I., Hidalgo, S., Santiago, L., Galvez, E.M., Arias, M., Pardo, J., 2022. Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison. FEBS J. 289, 4398-4415.
    Dent, R., Cortes, J., Pusztai, L., McArthur, H., Kummel, S., Bergh, J., Denkert, C., Park, Y.H., Hui, R., Harbeck, N., et al., 2024. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J. Natl. Cancer. Inst. 116, 1654-1663.
    Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A.P., Zhu, Z., Zhang, J., Benson, D.M., He, K., Caligiuri, M.A., et al., 2019. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 9, 1422-1437.
    Eskander, G., Abdelhamid, S.G., Wahdan, S.A., Radwan, S.M., 2025. Insights on the crosstalk among different cell death mechanisms. Cell. Death. Discov. 11, 56.
    Faget, D.V., Luo, X., Inkman, M.J., Ren, Q., Su, X., Ding, K., Waters, M.R., Raut, G.K., Pandey, G., Dodhiawala, P.B., et al., 2023. P38mapkalpha stromal reprogramming sensitizes metastatic breast cancer to immunotherapy. Cancer Discov. 13, 1454-1477.
    Fan, J., Lu, F., Qin, T., Peng, W., Zhuang, X., Li, Y., Hou, X., Fang, Z., Yang, Y., Guo, E., et al., 2023. Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance. Nat. Genet. 55, 2175-2188.
    Fernald, K., Kurokawa, M., 2013. Evading apoptosis in cancer. Trends. Cell. Biol. 23, 620-633.
    Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M.J., Powell, S.F., et al., 2018. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078-2092.
    Gong, J.H., Maki, G., Klingemann, H.G., 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 652-658.
    Guo, C., Qu, X., Tang, X., Song, Y., Wang, J., Hua, K., Qiu, J., 2023. Spatiotemporally deciphering the mysterious mechanism of persistent HPV-induced malignant transition and immune remodelling from HPV-infected normal cervix, precancer to cervical cancer: Integrating single-cell RNA-sequencing and spatial transcriptome. Clin. Transl. Med. 13, e1219.
    Halle, S., Halle, O., Forster, R., 2017. Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo. Trends. Immunol. 38, 432-443.
    Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., Chen, H., 2025. The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies. Front. Immunol. 16, 1512509.
    Herbst, R.S., Kurzrock, R., Hong, D.S., Valdivieso, M., Hsu, C.P., Goyal, L., Juan, G., Hwang, Y.C., Wong, S., Hill, J.S., et al., 2010. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer. Res. 16, 5883-5891.
    Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
    Howe, K.L., Achuthan, P., Allen, J., Allen, J., Alvarez-Jarreta, J., Amode, M.R., Armean, I.M., Azov, A.G., Bennett, R., Bhai, J., et al., 2021. Ensembl 2021. Nucleic. Acids. Res. 49, D884-D891.
    Hu, J., Zhang, L., Xia, H., Yan, Y., Zhu, X., Sun, F., Sun, L., Li, S., Li, D., Wang, J., et al., 2023. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome. Med. 15, 14.
    Hu, S., Lu, H., Xie, W., Wang, D., Shan, Z., Xing, X., Wang, X.M., Fang, J., Dong, W., Dai, W., et al., 2022. TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. J Clin. Invest. 132.
    Huang, C.X., Lao, X.M., Wang, X.Y., Ren, Y.Z., Lu, Y.T., Shi, W., Wang, Y.Z., Wu, C.Y., Xu, L., Chen, M.S., et al., 2024. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell 42, 2082-2097.
    Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R.K.S., et al., 2021. Synergism of tnf-alpha and ifn-gamma triggers inflammatory cell death, tissue damage, and mortality in sars-cov-2 infection and cytokine shock syndromes. Cell 184, 149-168.
    Kesavardhana, S., Malireddi, R.K.S., Kanneganti, T.D., 2020. Caspases in cell death, inflammation, and pyroptosis. Annu. Rev. Immunol. 38, 567-595.
    Kim, D., Paggi, J.M., Park, C., Bennett, C., Salzberg, S.L., 2019. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907-915.
    Kim, N., Kim, H.K., Lee, K., Hong, Y., Cho, J.H., Choi, J.W., Lee, J.I., Suh, Y.L., Ku, B.M., Eum, H.H., et al., 2020. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 11, 2285.
    Klingemann, H., 2023. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy 25, 451-457.
    Krishna, C., DiNatale, R.G., Kuo, F., Srivastava, R.M., Vuong, L., Chowell, D., Gupta, S., Vanderbilt, C., Purohit, T.A., Liu, M., et al., 2021. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 39, 662-677.
    Laughney, A.M., Hu, J., Campbell, N.R., Bakhoum, S.F., Setty, M., Lavallee, V.P., Xie, Y., Masilionis, I., Carr, A.J., Kottapalli, S., et al., 2020. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 26, 259-269.
    Lee, J., Kim, E.H., 2023. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy. Front. Oncol. 13, 1233376.
    Liu, H., Gao, J., Feng, M., Cheng, J., Tang, Y., Cao, Q., Zhao, Z., Meng, Z., Zhang, J., Zhang, G., et al., 2024. Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. Cancer Cell 42, 1067-1085.
    Martinez-Limon, A., Joaquin, M., Caballero, M., Posas, F., de Nadal, E., 2020. The p38 Pathway: From Biology to Cancer Therapy. Int. J. Mol. Sci. 21.
    Morcillo-Martin-Romo, P., Valverde-Pozo, J., Ortiz-Bueno, M., Arnone, M., Espinar-Barranco, L., Espinar-Barranco, C., Garcia-Rubino, M.E., 2025. The role of NK cells in cancer immunotherapy: mechanisms, evasion strategies, and therapeutic advances. Biomedicines 13.
    Nederlof, I., Isaeva, O.I., de Graaf, M., Gielen, R., Bakker, N.A.M., Rolfes, A.L., Garner, H., Boeckx, B., Traets, J.J.H., Mandjes, I.A.M., et al., 2024. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat. Med. 30, 3223-3235.
    Nikolic, I., Cursons, J., Shields, B., Chappaz, S., Sudholz, H., Meng, X., Constantinescu, P., Vijayakumaran, R., D'Angelo, M., Foroutan, M., et al., 2025. Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. Cancer Cell 43, 2034-2050.
    Nowicki, T.S., Hu-Lieskovan, S., Ribas, A., 2018. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer. J. 24, 47-53.
    Pan, R., Ryan, J., Pan, D., Wucherpfennig, K.W., Letai, A., 2022. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell 185, 1521-1538.
    Prager, I., Watzl, C., 2019. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J. Leukoc. Biol. 105, 1319-1329.
    Sade-Feldman, M., Jiao, Y.J., Chen, J.H., Rooney, M.S., Barzily-Rokni, M., Eliane, J.P., Bjorgaard, S.L., Hammond, M.R., Vitzthum, H., Blackmon, S.M., et al., 2017. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136.
    Saetersmoen, M., Kotchetkov, I.S., Torralba-Raga, L., Mansilla-Soto, J., Sohlberg, E., Krokeide, S.Z., Hammer, Q., Sadelain, M., Malmberg, K.J., 2025. Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor. Med. 6, 100521.
    Salome, B., Sfakianos, J.P., Ranti, D., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A.M., Ruan, D.F., et al., 2022. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 40, 1027-1043.
    Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Ribas, A., 2017. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707-723.
    Shen, Y., Ren, Y., Chen, K., Cen, Y., Zhang, B., Lu, W., Xu, J., 2022. The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma. Oncogenesis 11, 43.
    Shi, Y., Zhang, Q., Bi, H., Lu, M., Tan, Y., Zou, D., Ge, L., Chen, Z., Liu, C., Ci, W., et al., 2022. Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing. Genome. Biol. 23, 87.
    Silke, J., Meier, P., 2013. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold. Spring. Harb. Perspect. Biol. 5, a008730.
    Sturm, M., Schroeder, C., Bauer, P., 2016. SeqPurge: highly-sensitive adapter trimming for paired-end NGS data. BMC. Bioinformatics. 17, 208.
    Tang, F., Li, J., Qi, L., Liu, D., Bo, Y., Qin, S., Miao, Y., Yu, K., Hou, W., Li, J., et al., 2023. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235-4251.
    Taylor, B.C., Sun, X., Gonzalez-Ericsson, P.I., Sanchez, V., Sanders, M.E., Wescott, E.C., Opalenik, S.R., Hanna, A., Chou, S.T., Van Kaer, L.,et al., 2024. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer. Cancer Discov. 14, 290-307.
    Tie, Y., Tang, F., Wei, Y.Q., Wei, X.W., 2022. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J. Hematol. Oncol. 15, 61.
    Torrejon, D.Y., Abril-Rodriguez, G., Champhekar, A.S., Tsoi, J., Campbell, K.M., Kalbasi, A., Parisi, G., Zaretsky, J.M., Garcia-Diaz, A., Puig-Saus, C., et al., 2020. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 10, 1140-1157.
    Tsuchiya, Y., Nakabayashi, O., Nakano, H., 2015. FLIP the switch: regulation of apoptosis and necroptosis by cFLIP. Int. J. Mol. Sci. 16, 30321-30341.
    Uddin, S., Majchrzak, B., Woodson, J., Arunkumar, P., Alsayed, Y., Pine, R., Young, P.R., Fish, E.N., Platanias, L.C., 1999. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274, 30127-30131.
    Waldman, A.D., Fritz, J.M., Lenardo, M.J., 2020. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651-668.
    Wang, L., Jin, H., Jochems, F., Wang, S., Lieftink, C., Martinez, I.M., De Conti, G., Edwards, F., de Oliveira, R.L., Schepers, A., et al., 2022. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat. Cancer 3 1284-1299.
    Wang, Z., Li, Z., Zhou, K., Wang, C., Jiang, L., Zhang, L., Yang, Y., Luo, W., Qiao, W., Wang, G., et al., 2021. Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. Nat. Commun. 12, 6500.
    Xue, R., Zhang, Q., Cao, Q., Kong, R., Xiang, X., Liu, H., Feng, M., Wang, F., Cheng, J., Li, Z., et al., 2022. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141-147.
    Yoshida, T., Maeda, A., Tani, N., Sakai, T., 2001. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS. Lett. 507, 381-385.
    Yost, K.E., Satpathy, A.T., Wells, D.K., Qi, Y., Wang, C., Kageyama, R., McNamara, K.L., Granja, J.M., Sarin, K.Y., Brown, R.A., et al., 2019. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251-1259.
    You, J., Yang, X., Zhao, J., Chen, H., Tang, Y., Ouyang, D., Liu, Y., Wang, Y., Xie, S., Chen, Y., et al., 2025. Enhancing CAR-T cell metabolic fitness and memory phenotype for improved efficacy against hepatocellular carcinoma. Int. J. Biol. Sci. 21, 4231-4251.
    Zhang, M., Hu, S., Min, M., Ni, Y., Lu, Z., Sun, X., Wu, J., Liu, B., Ying, X., Liu, Y., 2021. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut 70, 464-475.
    Zhang, S., Fang, W., Zhou, S., Zhu, D., Chen, R., Gao, X., Li, Z., Fu, Y., Zhang, Y., Yang, F., et al., 2023a. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Nat. Commun. 14, 5123.
    Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A.T.F., Elisseeff, J., Popel, A.S., Anders, R.A., et al., 2023b. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome. Med. 15, 72.
    Zhao, Y., Cao, Y., Chen, Y., Wu, L., Hang, H., Jiang, C., Zhou, X., 2021. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology 164, 507-523.
    Zheng, Y., Chen, Z., Han, Y., Han, L., Zou, X., Zhou, B., Hu, R., Hao, J., Bai, S., Xiao, H., et al., 2020. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat. Commun. 11, 6268.
    Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al., 2020. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat. Commun. 11, 6322.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (54) PDF downloads (0) Cited by ()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return